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Abstract
Since RNA interference (RNAi) has the potential to discriminate between single nucleotide changes, there is growing
interest in the use of RNAi as a promising therapeutical approach to target dominant disease-associated alleles. Mutations in
the leucine-rich repeat kinase 2 (LRRK2) gene have been linked to dominantly inherited Parkinson’s disease (PD). We
focused on three LRRK2 mutations (R1441G/C and the more prevalent G2109S) hoping to identify shRNAs that would both
recognize and efficiently silence the mutated alleles preferentially over the wild-type alleles. Using a luciferase-based
reporter system, we identified shRNAs that were able to specifically target the R1441G and R1441C alleles with 80%
silencing efficiency. The same shRNAs were able to silence specifically mRNAs encoding either partial or full-length mutant
LRRK2 fusion proteins, while having a minimal effect on endogenous wild-type LRRK2 expression when transfected in 293FT
cells. Shifting of the mutant recognition site (MRS) from position 11 to other sites (4 and 16, within the 19-mer window of
our shRNA design) reduced specificity and overall silencing efficiency. Developing an allele-specific RNAi of G2019S was
problematic. Placement of the MRS at position 10 resulted in efficient silencing of reporters (75–80%), but failed to
discriminate between mutant and wild-type alleles. Shifting of the MRS to positions 4, 5, 15, 16 increased the specificity of
the shRNAs, but reduced the overall silencing efficiency. Consistent with previous reports, these data confirm that MRS
placement influences both allele-specificity and silencing strength of shRNAs, while further modification to hairpin design or
MRS position may lead to the development of effective G2019S shRNAs. In summary, the effective shRNA against LRRK2
R1441 alleles described herein suggests that RNAi-based therapy of inherited Parkinson’s disease is a viable approach
towards developing effective therapeutic interventions for this serious neurodegenerative disease.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disease causing
movement disorders including bradykinesia, rigidity and resting
tremors that are accompanied by pathological signs of dopamine
neuron degeneration in the substantia nigra area of midbrain.
Although most cases are thought to be sporadic, studies of familial
PD have revealed a number of genes to have a causative and
associated role in the disease. First characterized in genetic studies
of affected families in England and in the Basque region in
northern Spain [1,2], mutations in leucine-rich repeat kinase 2
(LRRK2) have been identified as the underlying cause of up to
10% of familial PD cases and 2–3% of sporadic cases, with varying
numbers and allele distribution depending upon the populations
studied [3,4]. LRRK2 is a complex 280 kD protein with multiple
domains that mediate protein interactions and subcellular
distribution, and possess enzymatic activity. Recent studies suggest
an interplay between LRRK2 and other proteins that have been
implicated with PD, including alpha-synuclein, parkin, and PINK-
1 [5,6,7,8]. At present, most evidence suggests that LRRK2
mutations cause an overall gain-of-function that leads to
neurotoxic effects, consistent with the observed autosomal-
dominant mode of inheritance.
In describing the molecular action of LRRK2, two domains
with enzymatic activity have been of particular focus, namely the
GTPase (termed ROC or Ras of complex proteins) and kinase
domains. The most prevalent LRRK2 mutations affect the two
domains involved with enzymatic activity, indicative of their
functional importance. The originally described Basque mutation
R1441G lies within the ROC GTPase domain, and more recently
identified mutations affecting the same amino acid (R1441C,
R1441H) have been described in affected PD patients [9,10,11].
There is ongoing controversy in the literature about the positive or
negative effects of these mutations on GTPase activity [12,13,14]
but what remains clear is that the ROC domain modulates kinase
activity, LRRK2 folding and dimer formation [15,16,17,18,19].
Overall, the most prevalent LRRK2 mutation is G2019S and
affects the serine-threonine kinase domain. From large population
studies, the estimated prevalence of this mutation is 1% of global
PD cases, 6% of inherited and 3% of sporadic PD cases in
European populations, and up to 42% in North African
populations [3,4]. Functional studies suggest that this mutation
leads to increased kinase activity, affecting both autophosphory-
lation [20,21,22,23] and the phosphorylation of other substrates,
such as the ezrin-radixin-moesin family of proteins [24]. This may,
in turn, influence actin-related events in neurite outgrowth [25].
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drug-based therapeutic approaches [26,27].
Another promising intervention approach to genetic diseases
lies in the development and application of therapies based upon
RNAi [28,29,30,31,32]. This conserved pathway uses short 21–
25-mer double-stranded RNA molecules to regulate gene
expression, through the control of mRNA stability and translation.
Briefly, siRNAs are unwound, with one strand (the guide strand)
being loaded into the RNA-induced silencing complex (RISC).
The loaded RISC then scans the mRNA pool until finding a
complementary target, leading to a cleavage of the target mRNA
at a position corresponding to nucleotide position 10/11 of the
guide strand [33]. When the mechanism underlying RNAi was
initially described, it implied that short-interfering RNAs (siRNAs)
may be able to discriminate between two sequences differing by a
single nucleotide. Capitalizing on this capability, it may ultimately
permit the exclusive targeting of only the disease-causing mRNAs,
while leaving the corresponding wild-type mRNA unaffected to
carry out its normal function. Indeed, recent studies have shown
that allele-specific silencing by RNAi (ASP-RNAi) is possible and
has been applied to disease-causing alleles linked to spinocerebellar
ataxia [34,35,36,37], Alzheimer’s [38] and Huntington’s disease
[39,40,41,42], and hereditary amyotrophic lateral sclerosis
[40,43,44,45,46,47], among others. While initial studies suggested
that central positioning of the ‘‘mutant recognition site’’ (MRS) for
ASP-RNAi allowed good discrimination, other studies have shown
that off-center positioning showed improvements, especially in the
case of purine:purine mismatches [40].
In this study, we have investigated whether ASP-RNAi may be
a feasible approach for the treatment of LRRK2-based Parkin-
son’s disease. Our results show that the G2019S allele may be
somewhat resistant to ASP-RNAi and MRS positioning influences
the balance between silencing strength and allele-specificity. In
contrast, the R1441G/C alleles are efficiently identified and
targeted when the MRS is centrally located. Since efficient
targeting of particular mRNA sequences is likely dependent on
multiple intrinsic and extrinsic factors (e.g. RNA secondary
structure or positioning of RNA-binding proteins), development
of efficient RNAi tools will depend on both informatic predictions
and empirical testing.
Results
To induce RNAi, we decided to use short hairpin RNA
(shRNA) as our model system. Although many advances have
been made in the packaging and delivery of siRNAs across the
blood-brain barrier [30,32], shRNAs can be expressed transiently
to test their efficacy and stability for long-term silencing, and can
be tailored for potential use in gene- or cell-based therapy. Of the
various vector configurations available, we chose to use the
pSM2c-shRNAmir system [48], which is able to generate siRNA
from shRNA more efficiently than other systems due to native
processing by Drosha and Dicer enzymes of the miR30-based
transcript into which the shRNA is embedded. Suitable control
vectors were also available that efficiently silenced exogenous
genes such as GFP. shRNAs were designed as 97-mer oligonucle-
otides, amplified by PCR and cloned into pSM2c (Figure 1).
For the proposed studies, we used the psiCHECK-2 vector
(Promega) as a reporter system. The target sequence of choice is
placed within the 39UTR of an expression cassette of Renilla
luciferase (Rluc; from Renilla reniformis), such that Rluc activity
(measurable by luminescence assay) is correlated with the silencing
potential of the test shRNAs. Also located within the same plasmid
is an internal control cassette encoding firefly luciferase (FFluc;
derived from Photinus pyralis). We used this system to clone short
400 bp fragments of the human LRRK2 gene that encompassed
our region of interest (Figure 1). Ten different constructs were
prepared: four were taken from the DNA encoding the ROC
domain, five from the kinase domain, and one from a distinct site
in LRRK2 (SM2-656; not shown in schematic diagram).
Targeting of LRRK2 R1441G mutation is effective with
central MRS
Transient transfections into 293FT cells were performed with
combinations of shRNA expression plasmids and luciferase
reporter targets. To determine specificity, shRNAs were tested
against wild-type and mutant targets and results were normalized
to FFLuc and those obtained with a non-targeting shRNA (SM2-
GFP). For targeting LRRK2 R1441G, we designed three shRNA
constructs that varied the position of the MRS. As shown in
Figure 2, we observed the best combination of silencing strength
and allele-specificity when the MRS was placed at position 11
[shRNA SM2-RG(11)]. Although weak recognition of the wild-
type allele was seen, the R1441G allele was targeted with 17.8-fold
higher efficiency for an overall silencing strength of 80%. Shifting
of the MRS to the ‘‘seed’’ region [position 4; SM2-RG(4)] or
position 16 [SM2-RG(16)] reduced both specificity and silencing
strength towards the R1441G target (4.7-fold and 3.1-fold, 35%
and 49%, respectively).
Targeting of LRRK2 R1441C mutation is equally effective
The R1441 residue of LRRK2 is a hotspot for mutation, with
Gly/Cys/His variants described to date. This suggests an
important structural and/or regulatory role for R1441, which is
contained within the ROC GTPase domain. Based upon our
evidence that MRS position 11 was effective for targeting the
R1441G allele, we prepared an additional shRNA and luciferase
target corresponding to R1441C. As shown in Figure 2C, SM2-
RC(11) efficiently targeted the R1441C reporter (81% overall
silencing strength) and moreover distinguished it from the wildtype
reporter (13.4-fold specificity). In addition, the mutant R1441G
reporter was poorly targeted by SM2-RC(11) (data not shown).
Based on these results, we conclude that locating the MRS at
position 11 optimizes the specific discrimination of R1441 alleles.
Targeting of LRRK2 R1441G mutation is effective using
additional reporters
Because LRRK2 is encoded by a long mRNA transcript (Refseq
NM_198578.3; 9239 bp; ORF 7584 bp), mRNA secondary
structure could be a contributing factor in targeting efficiency of
shRNAs. We therefore tested longer targets using a different
reporter context. We used truncated GFP-fusions as additional
reporters for gene-silencing that would display LRRK2 mRNA
structure in a more native context. We generated three GFS-fusion
constructs encompassing the ROC-COR-KINASE (RCK) do-
mains of LRRK2, containing 2517 bp of LRRK2 sequence, either
as wild-type or with mutations (R1441G in the ROC domain or
G2019S in the kinase domain), and used them to establish stable
293FT cell lines. The GFS-RCK fusions were localized diffusely
throughout the cytoplasm and excluded from the nucleus, and
mutations did not alter the pattern. Expression levels of the
transgene between the three cell lines were comparable and the
fusion proteins were detectable with FLAG or GFP antibodies
(Figure 3A–E).
We tested SM2-RG(11) and SM2-RG(16) for targeting of GFS-
fusion reporters and they yielded similar results of moderate
silencing strength and good specificity (Figure 3E–F). Compared to
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ing strength but maintained high specificity (40%, 19.8-fold;
respectively), whereas SM2-RG(16) resulted in slightly reduced
silencing strength but increased specificity (35%, 17.2-fold;
respectively). The negative control SM2-656(NR), designed to
target a distinct LRRK2 sequence not included in the RCK-
encoding region, had little effect on either GFP-fusion, whereas
the positive control SM2-GFP potently silenced both. We still
wondered whether ASP-RNAi was possible in full-length LRRK2,
so we obtained (or generated) MYC-tagged constructs for testing
of the SM2-RG(11) and SM2-RC(11) shRNAs. Although we were
unable to perform quantitation on blots from these experiments
due to background, it is qualitatively apparent that each allele-
specific shRNA is able to silence its cognate target in the full-length
context, with reduced or no effect on non-cognate targets
(Figure 3G). The positive control SM2-656 shRNA can silence
all LRRK2 variants (WT, R1441G, and R1441C), whereas the
negative control SM2-GFP has no effect. Taken together, these
results demonstrate the importance of using different reporter
systems and support our conclusion that effective R1441 allele-
specific targeting can be accomplished.
Targeting of LRRK2 G2019S mutation is less effective
Since its description as a gene underlying familial PD, multiple
alleles have been described in LRRK2, with the most prevalent
being G2019S, which is located in the kinase domain. This allele is
associated with 4–6% of cases of inherited PD [3,4]. We initially
designed 3 shRNAs to target the G2019S allele, varying the MRS
position to assess effects on silencing specificity and strength (see
Figure 1 for schematics). When tested using luciferase-based
reporters, a centrally located MRS [SM2-GS(10)] was able to
induce potent silencing of the LRRK2 template (80%), but was not
able to discriminate between the wildtype and G2019S alleles
(Figure 4A–B). Outward shifting of the MRS, either towards
position 5 (the ‘‘seed-region’’ area; nomenclature derived from
microRNAs) or towards position 15, led to an increase in the
allele-specific recognition of G2019S (up to 2.8-fold), but also led
to a decrease in silencing strength (35%).
We tested an additional shRNA with the MRS in position 4
[SM2-GS(4)] and it exhibited a slight increase in specificity over
SM2-GS(5), demonstrating that stepwise moves in MRS can alter
shRNA properties. A recent study focused on ASP-RNAi
optimization using siRNAs suggested that position 16 was
particularly suited for locating the MRS, especially in the case of
purine-purine mismatches [40]. For this reason we designed and
tested an additional shRNA [SM2-GS(16)] to determine whether
any improvements could be observed. Although the silencing
strength remained moderate (34%), this shRNA exhibited the best
specificity for G2019S (almost 10-fold over WT) of the five
shRNAs tested. We used the GFS-RCK cell lines to test SM2-
GS(10) and SM2-GS(16) and results correlated with the luciferase
assays, and furthermore, similar luciferase results were obtained
when co-transfections were followed by transient puromycin
selection (to confirm presence of SM2 plasmids) (data not shown).
While the SM2-GS(16) is promising, we conclude that efficient
allele-specific silencing of the G2019S allele is problematic and will
require the testing of additional hairpin designs or switching to
synthetic siRNA approach.
Finally, we tested whether selected shRNAs had any effect on
the expression of endogenous LRRK2 expression. (Figure 4C).
Using quantitative real-time PCR, we found that LRRK2
mRNA is expressed at moderate levels (compared to GAPDH)
in 293FT cells (derived from human embryonic kidney). Perhaps
this is not surprising since that, in addition to neural tissues,
Figure 1. Overview of LRRK2 domains with shRNA and reporter template design. LRRK2 is a large protein (280 kD) composed of multiple
domains [51]. Although PD-linked mutations have been described throughout the protein, only mutations addressed in this work that affect the ROC
and kinase domains are shown. A. Schematic design of shRNAs to target ROC-associated mutations is shown, illustrating the MRS shifts and the
nomenclature used. Numbering is according to 59 to 39 position in the antisense ‘‘guide’’ strand. The shRNAs were expressed from U6 promoter-
based SM2c, and a post-Drosha/pre-Dicer version is depicted. Portions of the WT and mutant LRRK2 target sequences are shown, which were
centrally located in a stretch of 400 bp included in the pSICHECK-2 vectors. B. The design of shRNAs and templates to target the G2019S kinase
mutation is shown. ANK: Ankyrin-like, LRR: Leucine-rich repeats, ROC: Ras of Complex proteins, COR: C-terminal of ROC, WD40:40 amino acid WD (or
beta-transducin) repeats.
doi:10.1371/journal.pone.0021352.g001
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heart and notably, the kidney [49,50]. A positive control shRNA
(SM2-656) showed .80% reduction of LRRK2 expression in
293FT cells (a similar reduction was observed using this shRNA
and a matched cognate template by luciferase reporter assay;
data not shown). Consistent with results obtained by luciferase
assay, we observed that the shRNA SM2-GS(10) strongly
silences endogenous LRRK2 (83%), even with a mismatch in
place. On the contrary, the best candidate shRNAs for R1441G
[SM2-RG(11)] and G2019S [SM2-GS(16)] showed only slight
reduction of the endogenous LRRK2 mRNA (3% and 12%,
respectively). We also tested whether these shRNAs could reduce
amount of endogenous LRRK2 protein by immunoblotting.
Perhaps due to its size or solubility, levels of LRRK2 protein
were exceeding low in cell lysates, however successful detection
of LRRK2 in 293FT cells was possible after immunoprecipita-
tion. Using this strategy, we show that, while SM2-656 can
effectively reduce endogenous LRRK2 levels, SM2-RG(11) and
SM2-RC(11) only weakly affect endogenous LRRK2 levels
compared to a negative control (SM2-GFP). Taken together,
these results further support the utility of these shRNAs for
allele-specific applications.
Figure 2. ASP-RNAi against R1441 LRRK2 alleles is effective when MRS is centrally located. A. Luciferase-based assays demonstrated that
shRNA SM2-RG(11) is quite selective in recognizing mutant over wild-type LRRK2, and leads to potent silencing of the mutant target. Shifting of the
MRS either 59 or 39 within the guide strand reduced both specificity and silencing strength of the resulting shRNAs. * denotes a p-value of ,0.01;
n.s.= not significant. B. A representation of fold-specificity is shown, calculated by comparing silencing strength of shRNA towards mutant templates
versus wild-type template (for example, 81% knockdown of R1441G by SM2-RG(11) compared to 4.5% knockdown of wild-type R1441 results in 17.8-
fold specificity). C. Similar experiments using a distinct shRNA and template to test R1441C ASP-RNAi showed that placing the MRS at position 11 is
also effective for a different R1441 allele.
doi:10.1371/journal.pone.0021352.g002
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LRRK2 and RNAi-based therapies of neurodegenerative
diseases
Mutations in LRRK2 are the most common cause of familial PD
and also appear in sporadic cases of idiopathic PD [3,4]. Initial
studies uncovered the R1441-type and G2019S mutations that
affect the ROC GTPase and kinase domains (respectively), which
led us to focus on experiments designed to enhance our
understanding of the effect of these mutations on LRRK2 function.
These mutations act dominantly and most likely cause enzymatic or
structural gain-of-function that lead to neuronal toxicity [51]. The
two enzymatic domains may be inter-dependent, with studies
suggesting that GTPase activity influences kinase activity
[12,14,52,53]. In the case of the GTPase domain, structural studies
suggest that R1441 mutations could destabilize dimer formation
[16], although it is unclear whether GTPase activity is linked to
dimer formation [17]. Regarding the kinase, most reports show an
increase in kinase activity as a result of the G2019S mutation
[24,54,55]. LRRK2 itself is a substrate, and autophosphorylation or
phosphorylation of adjacent LRRK2 dimers could have functional
consequences, such as affecting its GTPase activity or binding to
partners such as 14-3-3 and MKK3/6/7 proteins [21,22,56,57].
LRRK2 kinase can target proteins of the ezrin/radixin/moesin
Figure 4. ASP-RNAi against G2019S LRRK2 alleles is most effective when MRS is not centrally located. A. Luciferase-based assays
demonstrated that shRNA SM2-GS(10) has potent silencing capability but cannot discriminate between mutant and wild-type G2019 alleles. Shifting
of the MRS either 59 or 39 within the guide strand increased the specificity of resulting shRNAs, but reduced their overall silencing strength. * denotes
a p-value of ,0.01. B. A representation of fold-specificity is shown, calculated by comparing silencing strength of shRNA towards mutant template
versus wild-type template. Average values were used for comparison. SM2-GS(16) was the best shRNA tested in this study in the compromise
between specificity and silencing strength, but only slightly better that SM2-GS(4). C. Quantitative real-time PCR analysis of selected shRNAs shows
that the effect of SM2-RG(11) and SM2-GS(16) on endogenous wild-type LRRK2 in 293FT cells is weak (3% and 12%, respectively) and therefore these
are promising shRNAs for developing ASP-RNAi for the associated mutant alleles. D) Endogenous LRRK2 protein is only weakly silencing by SM2-
RG(11) and SM2-RC(11) shRNAs, compared to the SM2-GFP control. A positive control, SM2-656, which targets a distinct region of WT LRRK2, is
effective at silencing. LRRK2 was detected by immunoprecipitation, and actin is detected in input fractions.
doi:10.1371/journal.pone.0021352.g004
Figure 3. ASP-RNAi using SM2-RG(11) is also effective using a different reporter system. A–D. Stable cell lines expressing the RCK
domains of LRRK as GFS-fusions showed similar cytoplasmic localization of the fusion proteins and similar expression levels. A’–C’ show F-actin
counterstaining with Alexa568-phalloidin, with regions depicted in A–C highlighted by a yellow box. RCK: ROC-COR-kinase, GFS: GFP-FLAG-STREP.
Scale bars: 5 mm A–C, 25 mm A’–C’. D. GFS-LRRK2(RCK) fusions (WT and variants) have expected size and are expressed at similar levels, as detected
using FLAG antibody. E–F. Western blot analysis of cells treated with the indicated shRNAs showed that SM2-RG(11) and SM2-RG(16) are similarly
effective at recognizing and reducing expression the GFS-RCK(R1441G) fusion protein. An shRNA targeting a non-relavant LRRK2 sequence [i.e.
outside of the RCK region, SM2-656(NR)] was used a negative control and, in conjunction with the GFS-RCK(WT) target, was used as a reference for
determining relative expression levels. GFP antibody was used to detect the GFS-LRRK2(RCK) fusions and band intensities were normalized to actin. G.
ASP-RNAi by SM2-RG(11) and SM2-RC(11) on exogenous full-length LRRK2. Combinations of shRNAs and 2xMYC-tagged LRRK2 (WT or mutants) were
transfected into 293FT cells and analyzed after 48 hrs by western blotting with MYC antibody, with actin shown as a loading control.
doi:10.1371/journal.pone.0021352.g003
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membrane and actin filaments, and LRRK2-induced phosphory-
lation of ERMs can impair neurite outgrowth [24,25]. While the
GTPase and kinase domains may be amenable to targeting by
small-molecule enzymatic inhibitors [26], similar domains in other
proteins may be secondarily targeted. Also, enzyme inhibitors will
likely target wild-type LRRK2 as well. For this reason, we explored
the use of ASP-RNAi as a method for targeting the dominant
disease-causing alleles of LRRK2.
To our knowledge, the present study is the first that rigorously
explores ASP-RNAi approaches to a gene linked to PD, with the
hopes of developing efficient therapeutic interventions. There have
been previously published reports of effective allele-specific
siRNAs and shRNAs against genes linked to other neurodegen-
erative diseases, emphasizing the current interest and feasibility of
this approach. Some examples include: ataxin 7 (spinocerebellar
ataxia type 7; [37]), ataxin 3 (Machado-Joseph disease; [36,58]),
amyloid precursor protein APP (Alzheimer’s disease;
[59,60,61,62]), prion protein (Creutzfeldt-Jakob disease; [63]),
and huntingtin (Huntington’s disease; [40,42,64,65,66]) and the
Cu/Zn superoxide dismutase gene SOD1 (hereditary amyotrophic
lateral sclerosis ALS; [40,44,45,46,67,68,69]).
Because of the difficulties associated with designing effective
ASP-RNAi against disease-causing gene alleles, other approaches
have also been proposed. Instead of designing highly specific
shRNAs that can discriminate between the wild-type and mutant
alleles, some investigators silence both alleles with the best shRNA
that can be identified while simultaneously supplying a cDNA
encoding a RNAi-resistant version of the gene of interest [35,47].
Due to the size of the cDNAs and difficulty of controlling
endogenous expression levels, this may not be ideal for some
genes, especially LRRK2. It has also been proposed that silencing
of both wild-type and mutant alleles may be tolerated and is
perhaps beneficial, such as the case with huntingtin [70]. Recent
knockout mouse studies suggest that LRRK2 may be dispensable
for development and maintenance of dopaminergic neurons
(which undergo degeneration in PD), but LRRK2 2/2 mice
suffer from renal defects linked to accumulated alpha-synuclein
and increased apoptosis [71,72]. Therefore a ‘‘non-allele-specific’’
RNAi approach may be feasible for LRRK2 if restricted to neural
tissues. These examples serve to illustrate that research into the
application of RNAi to neurodegenerative diseases is active,
effective, and evolving.
Efficient ASP-RNAi of LRRK2 for R1441 alleles
Since the first reports linking LRRK2 to PD, up to 80 mutations
have been described in studies encompassing .1000 families/
sporadic cases. We have focused on three of the most prevalent -
and best characterized of the mutations, which affect the ROC
domain (R1441G/R1441C) and the kinase domain (G2019S).
Unlike many of the LRRK2 mutations previously reported, these
three mutations have been linked to PD pathogenicity through
segregation analysis [4]. Our results show that these mutations,
especially those affecting R1441, are amenable to ASP-RNAi.
As seen in previous studies from others [40,63], we have found
that placement of the MRS within the siRNA/shRNA can
influence both the silencing strength and specificity. In our case, a
centrally located MRS in SM2-RG(10) was able to silence LRRK2
mutant R1441G better than wild-type (almost 18-fold better) with
an overall silencing strength of 80%. By keeping the MRS in the
same position, similar efficiencies were obtained for an shRNA
targeting R1441C. Both of these mutations are caused by
underlying missense mutations of the same nucleotide (protein
change R1441G is caused by cDNA change c.4321C.G;
R1441C is caused by c. 4321C.T). A third mutation affected
the same amino acid (R1441H) has been described, suggesting that
R1441 is a mutational ‘‘hotspot’’ [11]. Although we might expect
that R1441H would also be efficiently targeted, it is caused by a
mutation of a distinct adjacent nucleotide in the cDNA
(c.4322G.A), so the efficiency of targeting this site by ASP-RNAi
may also be distinct. In the case of R1441G, we have shown that
shifting the MRS away from the central location caused a drop in
both specificity and silencing strength.
In this study, we have used distinct reporter systems in cell-based
assays and note that SM2-RG(11) performed better in the
luciferase-based assay than the GFS-fusion-based assay (compare
Figures 2 and 3). While this may be linked to various experimental
factors, including length of LRRK2 sequence included in the
reporter, time elapsed before analysis of silencing, and sensitivity of
detection, it underscores the need to test shRNAs empirically by
multiple assays. We also show that ASP-RNAi of R1441 alleles also
works on full-length mRNAs. Importantly, the SM2-RG(11)
shRNA has minimal effect on endogenous LRRK2 as judged by
quantitative RT-PCR, while both RG(11) and RC(11) have
minimal effect on endogenous LRRK2 protein levels. Thus,
SM2-RG(11) isa good candidateto proceed intomore physiological
studies, perhaps in a recently described mouse model carrying the
human R1441G LRRK2 allele [73], or in patient-derived cell lines
made feasible by induced pluripotent stem cell technology [74].
ASP-RNAi of the LRRK2 G2019S allele is less efficient
Our attempts to develop shRNAs against LRRK2 G2019S
yielded a pair of shRNAs [SM2-GS(4) and SM2-GS(16)] that
showed good discrimination of the mutant allele (7-fold to 10-fold
over wild-type, respectively). However, these shRNAs showed only
low-to-moderate silencing strength (around 30%). A centrally-
located MRS gave more potent silencing, but showed no
discrimination between the mutant and wild-type alleles. As
mentioned earlier, in a recent study using synthetic siRNAs, position
16 for placement of the MRS has been shown to be a favorable
position for enhanced allele-selectivity, especially in cases of purine-
purine mismatches [40]. In the case of G2019S, which is caused by a
mutation in the cDNA of c.6055G.A, the effect of the purine-
purinemismatchisevidentandposition16leadstothehighestallele-
specificity of the 5 shRNAs tested. In the case of R1441G, which has
a pyrimidine-purine mismatch c.4321C.G, we observed that
placing the MRS in position 16 maintained allele-specificity, but
position 11 was superior. Both examples are consistent and in
agreement with the previous study [40], however we still believe that
bioinformatic predictions need to be tested empirically and reported.
This, in turn, will lead to better predictions.
Until more is known about the function of LRRK2 and whether
a 30% reduction of the G2019S allele would be enough to
improve the pathological outcome, efforts to further optimize
shRNAs to target this allele are important. It has been reported
that homozygous carriers of G2019S are indistinguishable in PD
clinical characteristics from heterozygous carriers [75], suggesting
that the mere presence rather than dosage of the G2019S allele is
perhaps more important for the abnormal phenotype. Matters are
further complicated by reports of incomplete penetrance, i.e. that
some G2019S carriers (identified amongst control individuals) fail
to exhibit symptoms of PD (reviewed in [4]). Certainly there is
more sequence space to explore within the ‘‘window’’ surrounding
the G2019S and perhaps a distinct MRS position will give the
desired high-specificity, potent shRNA. Another solution may be
to introduce additional mismatches beyond the mutation of
interest, which has been shown to enhance ASP-RNAi in a recent
study, especially in the case of shRNAs [63].
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the G2019S, the most prevalent LRRK2 allele, and may be able to
reach similar efficiencies to the R1441G and R1441C shRNAs we
have described here. While RNAi-based therapies for neural
tissues still face important issues such as delivery and cell-specific
targeting (reviewed in [28,29,30,31,32]), ASP-RNAi offers a
promising therapeutic approach to these as yet incurable diseases.
Materials and Methods
Plasmid construction for shRNAs and reporters
All shRNA expression plasmids were based on the retroviral
vector SM2c (OpenBiosystems; [48]). Long single-stranded oligos
containing hairpin-encoding sequences were amplified by PCR
using Phusion high-fidelity polymerase (Finnzymes), digested with
Xho1-EcoR1, and cloned into SM2c. As this vector is prone to
recombination, all plasmid preparations were checked by agarose
gel electrophoresis and sequenced to verify correct structure. Using
a human LRRK2 cDNA (provided by J. Perez-Tur; CSIC,
Valencia [1]), a fragment encompassing the RCK-COR-KINASE
domains was PCR amplified and cloned as Not1-BamH1
fragments into LL-GFS-puro (a modified version of Lentilox 3.7
[76]), which includes an N-terminal GFP-FLAG-STREP tag and
IRES-puro sequences. (Note: Lentilox 3.7 was provided by L. van
Parijs, MIT; map available by WWWsearch; the U6-RNAi
cassette has been removed; details of the plasmid construction
available upon request). LRRK2 mutations (R1441G, G2019S)
were similarly prepared in LL-GFS-puro by two-step overlapping
PCR. For luciferase-based targets, sequences were amplified by
PCR and cloned as Xho1-Not1 fragments in pSICHECK2
(Promega). For full-length LRRK2 targets, we obtained 2xMYC-
LRRK2 (WT and R1441C) from Addgene (courtesy of M.
Cookson). To obtain 2xMYC-LRRK2(R1441G), quickchange
site-directed mutagenesis using Phusion polymerase was per-
formed using oligos 469/470. All final constructs were verified by
DNA sequencing (Stabvida, Portugal). A list of oligos used for
these constructions is provided (Table S1).
Luciferase assays and analysis
All assays were performed in human embryonic kidney-derived
293FT cells (Invitrogen) cultured in DMEM supplemented with
10% FCS, glutamine, and antibiotics. Transfections were
performed in 24-well plates using Arrest-In reagent (Open-
Biosystems), plus 400 ng of SM2c and 100 ng of pSICHECK2
target plasmids. Lysates were prepared 48 hours after transfection
and measured using Dual-Luciferase reporter assay (Promega) in
96-well plates by a luminometer (Turner Biosystems, TD20/20).
All values for Renilla luciferase (linked to RNAi activity) were
normalized to firefly luciferase (internal control). Student t-tests
were performed to determine significance. Final values are
compiled from triplicate-well assays performed at at least twice.
Additional controls included SM2c-GFP (OpenBiosystems), which
expresses a potent shRNA targeting GFP, but gave negligible
activity against LRRK2 targets. To evaluate silencing strength and
specificity against mutant and wild-type targets, all SM2c hairpins
targeting LRRK2 were compared to a non-relevant target
corresponding to LRRK2 1-400.
Stable cell line production, shRNA treatment and analysis
Lentivirus was prepared by calcium phosphate transfection of
293FT using LL-GFS-LRRK2 plasmids and psPAX2/pVSV-G
[provided by D. Trono (EPFL, Lausanne) and L. van Parijs (MIT)]
for packaging. Filtered supernatants were titered and used to infect
293FT cells (MOI 5) and stable populations were selected by
puromycin treatment (0.5 mg/ml). For microscopic analysis, cells
were plated on poly-L-lysine-coated coverslips, counterstained
with Alexa568-phalloidin (Invitrogen) and imaged on a Leica TCS
SP2 confocal microscope. Using SM2 plasmids (2 mg), cell lines
were transfected using Arrest-In in 6-well plates. After 72 hours,
cells were lysed directly in 1x SDS sample buffer and analysed by
10% SDS-PAGE and by immunoblotting using FLAG (Sigma M2
mAb 1:3000) or GFP antibody (Santa Cruz sc8334; 1:1000).
Chemiluminesent signals were developed by SuperSignal West
Pico reagent (Pierce), and captured and quantified by Chemidoc
system and Quantity One software, respectively (Biorad). Excel,
Photoshop and Illustrator software (Microsoft; Adobe) was used for
statistical analysis and image preparation.
Quantitative real-time PCR analysis
Transfections were performed (2 mg DNA, 6-well) and cells
were collected after 48 hours. Total RNA was isolated using mi-
Total (Metabion), and cDNA was prepared using Thermoscript
reverse transcription (Invitrogen). Primer sequences were obtained
from qPrimerDepot (http://primerdepot.nci.nih.gov) and primer
efficiencies tested by sample dilution method. PCR reactions were
prepared using iQ SYBR Supermix (Biorad) and analyzed using
an iCycler (Biorad). Cycling conditions were 94uC3 9, (94uC, 150;
57uC1 5 0;7 2 uC3 0 0; 40x), followed by a melt-curve analysis. The
DDCt method was used to calculate relative expression levels of
LRRK2. The data presented is derived from triplicate PCRs of
cDNA from three independent experiments.
Endogenous LRRK2 detection by western blot
The shRNA transfections into 293FT were performed (10 mg
DNA, 10 cm dish) and cells were treated after 24 hours with
puromycin (0.5 mg/ml) to enrich for transfected cells. 72 hours
after transfection, cells were lysed in 500 ml M-PER (Pierce)
supplemented with protease inhibitors (Roche) and incubated at
1 hr, 4uC with agitation. After clearing by centrifugation, protein
concentration was checked by Bradford reagent (Biorad) and
500 mg of protein was used in each immunoprecipitation. Inputs
were saved as controls. LRRK2 mAb (Epitomics MJFF2; 5 ml) was
added to lysate on ice for 30 minutes, before adding 30 mlo f
washed Gammabind Plus Sepharose (GE Healthcare) for 4 hrs,
4uC with agitation. After 5 washes with M-PER supplemented
with 100 mM NaCl, beads were resuspended in sample buffer,
analyzed by 6% SDS-PAGE (controls by 10%), transferred to
PVDF membrane, and blocked in 5% nonfat milk, 0.1% Tween-
20 in PBS. Blots were probed using LRRK2 (MJFF2; 1:1000) or
actin (Sigma AC74, 1:5000), with IgG-light chain-specific
secondary antibodies (Jackson Immunoresearch). LRRK2 signals
were developed using SuperSignal West Femto reagent (Pierce).
Supporting Information
Table S1 Oligonucleotides used in this study.
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